This biotech's future is bright, but how good could it get for investors?
The stock is down more than 50% from its 52-week high.
New data indicate that its cell therapy could soon find a larger market.
These biotech stocks have just launched their first products.
These four small-cap stocks scan as deeply undervalued right now.
Investors are misunderstanding when the biopharma company's flagship drug will begin generating meaningful reportable revenue.
Iovance Biotherapeutics: Q1 Earnings Snapshot
The time to jump into a red-hot growth prospect is usually right now...before any more investors identify the opportunity.
Is this rising healthcare stock a good buy right now?
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential.